Rhythm Biosciences Says Cancer Test Early Commercial Adoption Program Hits Milestone; Shares Jump 5%

MT Newswires Live

Mar 30

Rhythm Biosciences (ASX:RHY) said that its ColoSTAT Access program, which provides a pathway for the early commercial adoption of its ColoSTAT cancer test reached 10 participating clinician sites across Victoria, New South Wales, and Queensland, according to a Monday Australian bourse filing.

Meanwhile, an additional 40 blood collection sites were activated as part of its commercial network rollout strategy with its partner 4Cyte Pathology, bringing the total to 78 activated commercial collection centers, per the filing.

The company's shares rose past 5% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2623606153"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623606153\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623606153?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 11:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623606153","market":"sh","top_or_hot":-1,"title":"Rhythm Biosciences Says Cancer Test Early Commercial Adoption Program Hits Milestone; Shares Jump 5%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) said that its ColoSTAT Access program, which provides a pathway for the early commercial adoption of its ColoSTAT cancer test reached 10 participating clinician sites across <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>, New South Wales, and Queensland, according to a Monday Australian bourse filing.</p><p>Meanwhile, an additional 40 blood collection sites were activated as part of its commercial network rollout strategy with its partner 4Cyte Pathology, bringing the total to 78 activated commercial collection centers, per the filing.</p><p>The company's shares rose past 5% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Biosciences Says Cancer Test Early Commercial Adoption Program Hits Milestone; Shares Jump 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Biosciences Says Cancer Test Early Commercial Adoption Program Hits Milestone; Shares Jump 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-30 11:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) said that its ColoSTAT Access program, which provides a pathway for the early commercial adoption of its ColoSTAT cancer test reached 10 participating clinician sites across <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>, New South Wales, and Queensland, according to a Monday Australian bourse filing.</p><p>Meanwhile, an additional 40 blood collection sites were activated as part of its commercial network rollout strategy with its partner 4Cyte Pathology, bringing the total to 78 activated commercial collection centers, per the filing.</p><p>The company's shares rose past 5% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2623606153","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623606153","pubTimestamp":1774841006,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rhythm Biosciences  said that its ColoSTAT Access program, which provides a pathway for the early commercial adoption of its ColoSTAT cancer test reached 10 participating clinician sites across Victoria, New South Wales, and Queensland, according to a Monday Australian bourse filing.Meanwhile, an additional 40 blood collection sites were activated as part of its commercial network rollout strategy with its partner 4Cyte Pathology, bringing the total to 78 activated commercial collection centers, per the filing.The company's shares rose past 5% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","RHY.AU":"RHYTHM BIOSCIENCES LTD"},"translate_title":"Rhythm Biosciences表示癌症测试早期商业采用计划达到里程碑；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHY.AU":1},"content_text":"Rhythm Biosciences (ASX:RHY) said that its ColoSTAT Access program, which provides a pathway for the early commercial adoption of its ColoSTAT cancer test reached 10 participating clinician sites across Victoria, New South Wales, and Queensland, according to a Monday Australian bourse filing.Meanwhile, an additional 40 blood collection sites were activated as part of its commercial network rollout strategy with its partner 4Cyte Pathology, bringing the total to 78 activated commercial collection centers, per the filing.The company's shares rose past 5% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}